Vertex Pharmaceuticals Logo

Email this page: News Release

Data from Phase 2 Study of an INCIVEK® Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12)

For security reasons, registration is required before you can use this feature.
* Indicates required field